This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia.
Leukemia research · 2026
Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changes.
Blood neoplasia · 2026
Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study.
Nephrology (Carlton, Vic.) · 2026
Latest funding
- $2,000,000
Allogeneic regulatory T cell therapy to prevent graft versus host disease
CIHR · 2024 · Principal investigator
8 publications.
Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia.
Li H, Wong T, Rouhi A, Abou-Mourad Y, Cherniawsky H, Chung S, Forrest D, Lad D, Nantel S, Narayanan S, Nevill T, Nguyen A, Panahi A, Bakharzi M, Parkin S, Piechnik C, Rodrigo J, Roy C, Sanford D, Stubbins RJ, Toze C, Varghese J, White J, Wong E, Sutherland H, Song K, Venner CP, Kuchenbauer F
Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changes.
Chornenki N, Fadul A, Supan A, Abou Mourad Y, Cherniawsky H, Chung S, Forrest D, Lad D, Karsan A, Kuchenbauer F, McGinnis E, Nantel S, Narayanan S, Nevill T, Rodrigo J, Roy C, Song K, Toze C, White J, Sanford D, Stubbins RJ
Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study.
Barak P, Divyaveer S, Pattanaik S, Kharbanda S, S PE, Subramani V, Kumar R, Kekan K, Behl S, Kashyap M, Prajapati K, Zohmangaihi D, Mallik N, Lad D, Premkumar M, Yadav R, Kaur M, Anandh U, Ramachandran R, Kohli HS
Randomized Controlled Trial Comparing Lactoferrin Plus Iron to Iron Alone for Iron Deficiency Anemia in CKD.
Divyaveer S, Kekan K, Kashyap M, Kaur M, Prajapati K, Premkumar M, Zohmangaihi D, Mallik N, Lad D, Jassal RS, Sharma A, Behl S, Patil AN, Kumar A, Rani L, Prabhahar A, Rathi M, Ramachandran R, Kohli HS
Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre Experience.
Kim JL, Joe MAB, Chung S, Cherniawsky H, Forrest DL, Kuchenbauer F, Lad D, Nantel SH, Narayanan S, Nevill TJ, Rodrigo J, Sanford D, Song KW, Stubbins RJ, Toze CL, White J, Abou Mourad Y, Roy C
Bridging the gap: the need for community-engaged research on blood cancer self-management experiences among South Asians
Dhillon S, Sirois AC, Sanghera D, Kaur A, Sasheendren A, Mian H, Newton L, Ahmed S, Cosco TD, Lad D
Randomized controlled trial of pre-transplant zoledronate versus observation for prevention of bone loss in allogeneic hematopoietic cell transplantation.
Khaire N, Bhattacharjee U, Dinesan A, Sinha A, Bhadada S, Pardeep A, Chhabra P, Sharma R, De R, Kaundal S, Kasudhan KS, Ks L, Singh C, Jandial A, Jain A, Prakash G, Khadwal A, Patil A, Malhotra P, Lad D
Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS.
Kt MF, Semwal M, Yoosuf BT, Lad D, Bansal D
Allogeneic regulatory T cell therapy to prevent graft versus host disease
Principal investigators: Levings, Megan K; Schultz, Kirk R; Ahmad, Imran; Dijke, Ilona E; Hay, Kevin A; Lad, Deepesh P; West, Lori J
Keywords: Cell Therapy; Graft Versus Host Disease; Regulatory T Cells; Tolerance; Transplantation
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Surgery
- Genome Sciences Centre
- Oncology
- Medicine/Oncology
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.